WEIGHTING ON BIG PHARMA –
Aug. 23, 2023 – Since the FDA approved once-weekly semaglutide injection in 2021 for chronic weight management for adults with obesity or overweight with at least one weight-related condition, a multibillion-dollar market for anti-obesity medications has followed. Injectable semaglutide 2.4 mg (Wegovy, Novo Nordisk) and its counterpart semaglutide 1 mg (Ozempic), approved to treat type 2 diabetes, are associated with weight loss of as much as 15% to 20% for some patients. The GLP-1 receptor agonists now dominate headlines — and celebrity weight loss speculation — in the mainstream press.
